Verastem, INC Form 4 insider transactions

Dan Paterson, President and CEO and a Director of Verastem, Inc., sold 1,302 shares of common stock on August 3, 2026 for $5.81 per share.

Verastem Inc. President and CEO Dan Paterson sold 20,871 shares of common stock to cover statutory withholding taxes upon the vesting of restricted stock units.

Verastem, Inc. CFO Daniel Calkins sold company stock to cover tax obligations related to vested restricted stock units.

Director Michael P. Bailey was granted 108,000 restricted stock units in Verastem, Inc. as part of an equity incentive plan.

Verastem, Inc. reports that Director Karin Tollefson acquired 36,000 shares of common stock through the vesting of RSUs on May 21, 2026.

Verastem, Inc. reports that Director Brian M. Stuglik was granted 36,000 Restricted Stock Units (RSUs) on May 21, 2026.

Verastem, Inc. reports that Director Eric K. Rowinsky was granted 36,000 Restricted Stock Units (RSUs) on May 21, 2026.

Verastem, Inc. reports a Form 4 filing detailing Michelle Robertson's acquisition of 36,000 common stock units.

Verastem, Inc. reports that Director Anil Kapur acquired 36,000 Restricted Stock Units (RSUs) on May 21, 2026, as part of his compensation under the company's equity incentive plan.

Verastem, Inc. director Paul A. Bunn was granted 36,000 Restricted Stock Units (RSUs) on May 21, 2026, as part of the company's 2021 Equity Incentive Plan.

Verastem, Inc. director John Johnson reported the acquisition of 36,000 shares of common stock.

Verastem Inc. reports a Form 4 filing detailing a transaction by President and CEO Dan Paterson involving the sale of common stock to cover statutory withholding taxes upon the vesting of restricted stock units.

Verastem's Chief Financial Officer, Daniel Calkins, sold 57 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Verastem's President and CEO, Dan Paterson, sold 970 shares of common stock to cover tax withholding requirements related to restricted stock unit vesting.

Verastem, Inc. Chief Financial Officer Daniel Calkins was granted 16,665 restricted stock units, aligning his interests with shareholders.

Verastem, Inc. CEO and Director Dan Paterson received a grant of 213,785 restricted stock units, vesting over three years.

Verastem's President and CEO, Dan Paterson, sold 10,321 shares of common stock at $7.16 per share to cover tax withholdings from restricted stock unit vesting.

Verastem's Chief Financial Officer, Daniel Calkins, sold 5,039 shares of common stock at $7.16 per share to cover tax withholdings from restricted stock unit vesting.

Verastem, Inc. has granted its President of Development, Michael Kauffman, 200,000 stock options with an exercise price of $6.88, vesting over three years.

Verastem's Chief Financial Officer, Daniel Calkins, sold 80 shares of common stock to cover tax withholding requirements related to restricted stock unit vesting.

Verastem Director Brian M Stuglik sold 592 shares of common stock at $9.14 per share to cover tax obligations related to restricted stock unit vesting, as part of a pre-planned transaction.

Verastem's President and CEO, Dan Paterson, sold 393 shares of common stock to cover tax withholding requirements related to restricted stock unit vesting.

Verastem Director Robert E. Gagnon reported the sale of 283 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Verastem, Inc. President and CEO, Dan Paterson, sold 4,000 shares of common stock in two transactions under a pre-arranged Rule 10b5-1 trading plan.

Verastem Inc.'s President and CEO, Dan Paterson, reported the sale of 6,000 shares of common stock across three transactions in early December 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Verastem, Inc. President and CEO, Dan Paterson, reported the sale of 6,000 shares of common stock over three days in December 2025, executed under a pre-arranged Rule 10b5-1 trading plan.

Verastem, Inc. President and CEO, Dan Paterson, sold 6,000 shares of common stock in late November and early December 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Verastem Director Paul A. Bunn exercised stock options and subsequently sold 6,250 shares of common stock for approximately $10.00 per share under a Rule 10b5-1 plan.

Verastem Director Michael Kauffman has filed a Form 4 indicating a planned sale of 8,550 shares of common stock on November 21, 2025, under a Rule 10b5-1 trading plan.

Verastem Inc.'s President and CEO, Dan Paterson, sold 6,000 shares of common stock for $60,000 through a pre-arranged Rule 10b5-1 trading plan.